Global Health Limited, which operates the Medanta hospital network, is one of India’s leading multi-specialty healthcare providers. Founded by Dr. Naresh Trehan, the company runs large tertiary and quaternary care hospitals in Delhi-NCR, Lucknow, Patna, Indore, and Noida, with expansion underway in other cities. Known for clinical excellence and premium healthcare delivery, Global Health has attracted strong institutional interest. However, its high valuation and recent profit decline warrant careful analysis. This article provides a fact-based outlook on its fundamentals and estimates a realistic share price target for 2026 through 2030.
Key Services: Cardiology, neurology, oncology, organ transplants, and critical care
Hospital Network: 6 operational hospitals (~2,700 beds); new facilities in Nagpur, Ranchi, and Gurugram under development
Listed On: BSE (543523) and NSE (MEDANTA)
Global Health: Key Financial Snapshot
Metric
Value
Market Capitalization
₹31,147.43 Cr
Enterprise Value
₹30,235.09 Cr
Current Share Price
₹1,159 (approx.)
P/E (TTM)
66.91
P/B (TTM)
8.04
Book Value (TTM)
₹144.15
EPS (TTM)
₹17.32
ROE
14.14%
ROCE
19.25%
Dividend Yield
0.04%
Sales Growth (YoY)
7.71%
Profit Growth (YoY)
-5.10%
Cash Reserves
₹1,052.78 Cr
Debt
₹140.44 Cr
Face Value
₹2
No. of Shares
26.88 Cr
Shareholding Pattern
Category
Holding (%)
Public (Retail)
42.46%
Promoters
33.01%
Domestic Institutions (DII)
13.99%
Foreign Institutions (FII)
10.54%
Others
0%
The promoter stake is held by Dr. Naresh Trehan and related entities. Public holding is unusually high for a mid-cap, indicating strong retail participation.
Global Health Share Price Target Forecast (2026–2030)
Based on the hospital expansion pipeline, healthcare sector tailwinds, historical valuation, and earnings trajectory, we estimate the following realistic price ranges:
Year
Target Price Range (₹)
2026
₹1,200 – ₹1,400
2027
₹1,300 – ₹1,550
2028
₹1,400 – ₹1,700
2029
₹1,500 – ₹1,850
2030
₹1,600 – ₹2,000
Year-wise Breakdown
Global Health Share Price Target 2026
Year
Share Price Target 1
Share Price Target 2
2026
₹1,200
₹1,400
Strong brand equity and operational scale support long-term value.
Recent profit dip (-5.1%) reflects pre-opening costs for new hospitals, not core weakness.
At P/E ~67x, valuation is rich—limits near-term upside unless earnings rebound sharply.
Global Health Share Price Target 2027
Year
Share Price Target 1
Share Price Target 2
2027
₹1,300
₹1,550
New hospitals in Nagpur and Ranchi are expected to start contributing revenue.
Rising medical tourism and private health insurance penetration boost demand.
If occupancy rates improve, EBITDA margins may expand from the current ~23%.
Global Health Share Price Target 2028
Year
Share Price Target 1
Share Price Target 2
2028
₹1,400
₹1,700
Full-year contribution from new facilities should drive top-line growth.
Recurring patient base and referral networks enhance revenue stability.
ROCE of 19.25% supports premium valuation if sustained.
Global Health Share Price Target 2029
Year
Share Price Target 1
Share Price Target 2
2029
₹1,500
₹1,850
By 2029, the company could operate 10+ hospitals with pan-India presence.
Focus on high-margin specialties (transplants, oncology) improves profitability.
Digital health initiatives may add new revenue streams.
Global Health Share Price Target 2030
Year
Share Price Target 1
Share Price Target 2
2030
₹1,600
₹2,000
As India’s private healthcare market grows, Medanta is well-positioned as a premium player.
However, high capex, regulatory risk, and intense competition cap explosive returns.
Realistic 2030 target assumes EPS of ₹24–28 and P/E of 55–60x.
Strengths vs Risks
✅ Strengths
Strong brand led by Dr. Naresh Trehan
High-quality infrastructure and clinical outcomes
Low debt (Debt/Equity < 0.1x) and healthy cash reserves
Beneficiary of rising healthcare spending and insurance coverage
⚠️ Risks
Extremely high P/E (67x) leaves little room for error
Negative profit growth despite revenue increase
Capital-intensive model delays ROI on new hospitals
Regulatory scrutiny on pricing and medical practices
Investment Suitability
Factor
Assessment
Risk Profile
High
Time Horizon
Long-term (5+ years)
Volatility
Moderate to High
Dividend/Income
Minimal (0.04% yield)
Ideal Investor
Believes in India’s private healthcare boom; can tolerate high valuation
FAQs
A realistic range is ₹1,200 to ₹1,400, based on current fundamentals and expansion plans.
We estimate ₹1,600 to ₹2,000 by 2030, assuming successful hospital ramp-up and margin improvement.
Reliable forecasts beyond 2030 are not possible. Such long-term projections are highly speculative and not supported by verifiable data.
Promoters hold 33.01%, led by founder Dr. Naresh Trehan. The rest is held by public (42.46%), DIIs (13.99%), and FIIs (10.54%).
Yes, but the dividend yield is extremely low at 0.04%. The company prioritizes reinvestment in hospital expansion.
The stock corrected due to -5.10% YoY profit decline, high valuation (P/E > 65x), and concerns over return on new investments.
It offers exposure to India’s growing private healthcare sector, but comes with high valuation risk and execution uncertainty. Suitable only for investors with a long horizon and high risk tolerance.
Final Verdict
Global Health (Medanta) is a high-quality healthcare franchise with strong clinical credentials and expansion momentum. However, its rich valuation and recent profit decline make it a risky near-term bet. Our 2026–2030 price targets (₹1,200–₹2,000) reflect cautious optimism, contingent on successful hospital scaling and margin recovery. Investors should monitor quarterly occupancy rates, EBITDA margins, and capex efficiency closely.
📌 Disclaimer: These targets are for educational purposes only and are not investment advice. Always consult a SEBI-registered advisor before investing.
Hi, I’m Raj Mittal, a stock market content writer focused on company analysis, share price trends, and fundamental research. I create simple, research-based insights to help investors make smarter market decisions.
